Tonix Pharmaceuticals Holding Corp. (TNXP) Financials

TNXP Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 257.9 million 30.8 million
Dec. 31, 2025 277.2 million 32.0 million
Sept. 30, 2025 252.4 million 21.3 million
June 30, 2025 187.4 million 19.4 million

TNXP Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -44.0 million 2.0 million
Dec. 31, 2025 -41.5 million 1.8 million
Sept. 30, 2025 -29.7 million 1.8 million
June 30, 2025 -17.4 million 1.4 million

TNXP Net Income

No data available :(

TNXP Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 185.5 million 1.1 million -
Dec. 31, 2025 207.6 million - 1.2 million
Sept. 30, 2025 190.1 million - 425000
June 30, 2025 125.3 million - 492000

TNXP Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 13.7 million
Dec. 31, 2025 8.5 million
Sept. 30, 2025 8.9 million
June 30, 2025 7.3 million

TNXP Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 1.7 million 18.2 million 28.1 million -
Dec. 31, 2025 1.9 million 16.9 million 35.2 million -
Sept. 30, 2025 962000 9.3 million 25.7 million -
June 30, 2025 2.5 million 10.8 million 16.2 million -

TNXP Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 6.9 million 2.1 million
Dec. 31, 2025 5.4 million 1.5 million
Sept. 30, 2025 3.3 million 1.4 million
June 30, 2025 2.0 million 3.3 million

TNXP

Price: $11.63

52 week price:
10.65
69.97

Payout Ratio Range:
-30.09%
-2.65%

Earnings Per Share: -14.66 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 943700

Ebitda: -5.8 million

Market Capitalization: 178.0 million

Links: